JP2018533949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533949A5 JP2018533949A5 JP2018521571A JP2018521571A JP2018533949A5 JP 2018533949 A5 JP2018533949 A5 JP 2018533949A5 JP 2018521571 A JP2018521571 A JP 2018521571A JP 2018521571 A JP2018521571 A JP 2018521571A JP 2018533949 A5 JP2018533949 A5 JP 2018533949A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant
- phagemid
- aav
- particle
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 53
- 210000004027 cell Anatomy 0.000 claims 30
- 239000013598 vector Substances 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 108700019146 Transgenes Proteins 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 238000004806 packaging method and process Methods 0.000 claims 9
- 230000008685 targeting Effects 0.000 claims 8
- 108090000565 Capsid Proteins Proteins 0.000 claims 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 230000010076 replication Effects 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 102000053602 DNA Human genes 0.000 claims 4
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 4
- 230000029142 excretion Effects 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims 3
- 210000000234 capsid Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000011065 in-situ storage Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241001515965 unidentified phage Species 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 239000013607 AAV vector Substances 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 229920002873 Polyethylenimine Polymers 0.000 claims 2
- 101710172711 Structural protein Proteins 0.000 claims 2
- 229920006317 cationic polymer Polymers 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000004020 luminiscence type Methods 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 101710094648 Coat protein Proteins 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 1
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 claims 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 101710141454 Nucleoprotein Proteins 0.000 claims 1
- 101710083689 Probable capsid protein Proteins 0.000 claims 1
- 102000007327 Protamines Human genes 0.000 claims 1
- 108010007568 Protamines Proteins 0.000 claims 1
- 241000256251 Spodoptera frugiperda Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- -1 cationic lipid Chemical class 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229950008679 protamine sulfate Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022075036A JP2022115934A (ja) | 2015-11-02 | 2022-04-28 | ファージミドベクター |
| JP2024076613A JP2024102282A (ja) | 2015-11-02 | 2024-05-09 | ファージミドベクター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1519303.0A GB201519303D0 (en) | 2015-11-02 | 2015-11-02 | Phagemid vector |
| GB1519303.0 | 2015-11-02 | ||
| PCT/GB2016/053366 WO2017077275A1 (en) | 2015-11-02 | 2016-10-31 | Phagemid vector |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022075036A Division JP2022115934A (ja) | 2015-11-02 | 2022-04-28 | ファージミドベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533949A JP2018533949A (ja) | 2018-11-22 |
| JP2018533949A5 true JP2018533949A5 (enExample) | 2019-10-24 |
| JP7068166B2 JP7068166B2 (ja) | 2022-05-16 |
Family
ID=55130522
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521571A Active JP7068166B2 (ja) | 2015-11-02 | 2016-10-31 | ファージミドベクター |
| JP2022075036A Pending JP2022115934A (ja) | 2015-11-02 | 2022-04-28 | ファージミドベクター |
| JP2024076613A Pending JP2024102282A (ja) | 2015-11-02 | 2024-05-09 | ファージミドベクター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022075036A Pending JP2022115934A (ja) | 2015-11-02 | 2022-04-28 | ファージミドベクター |
| JP2024076613A Pending JP2024102282A (ja) | 2015-11-02 | 2024-05-09 | ファージミドベクター |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11603540B2 (enExample) |
| EP (2) | EP4163382A1 (enExample) |
| JP (3) | JP7068166B2 (enExample) |
| CA (1) | CA3040230A1 (enExample) |
| DK (1) | DK3371315T3 (enExample) |
| GB (1) | GB201519303D0 (enExample) |
| WO (1) | WO2017077275A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519303D0 (en) | 2015-11-02 | 2015-12-16 | Imp Innovations Ltd | Phagemid vector |
| GB201706090D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Methods for adeno-associated viral vector production |
| CA3058970A1 (en) | 2017-04-18 | 2018-10-25 | Glaxosmithkline Intellectual Property Development Limited | Methods for adeno-associated viral vector production |
| GB201706451D0 (en) * | 2017-04-24 | 2017-06-07 | Imp Innovations Ltd | Cancer treatment |
| KR102877876B1 (ko) * | 2018-05-08 | 2025-10-28 | 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 | Aav-상용성 라미닌-링커 중합 단백질 |
| CA3104833A1 (en) * | 2018-07-16 | 2020-01-23 | Dcprime B.V. | A combination product for use in tumor vaccination. |
| EP3844289A4 (en) * | 2018-08-29 | 2022-07-20 | Shanghaitech University | COMPOSITION AND USE OF CAS PROTEIN INHIBITORS |
| GB201816919D0 (en) * | 2018-10-17 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Adeno-associated viral vector producer cell lines |
| CN110235467B (zh) * | 2019-04-30 | 2021-11-02 | 北京小米移动软件有限公司 | 小区重配方法及装置 |
| WO2022010813A2 (en) * | 2020-07-06 | 2022-01-13 | Rutgers, The State University Of New Jersey | Enhancing immune responses through targeted antigen expression |
| WO2022072324A1 (en) * | 2020-09-29 | 2022-04-07 | NeuExcell Therapeutics Inc. | Isl1 and lhx3 vector |
| WO2024149989A1 (en) * | 2023-01-10 | 2024-07-18 | Imperial College Innovations Limited | Phage vector |
| WO2024243134A2 (en) * | 2023-05-19 | 2024-11-28 | Academia Sinica | Engineered bacteriophage particle and method of gene therapy by using same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009690A2 (en) * | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| WO1999011764A2 (en) * | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| EP1660636A4 (en) | 2003-08-26 | 2009-07-01 | Univ Texas | VACCINES AGAINST CANCER |
| EP1960526A4 (en) | 2005-12-07 | 2009-07-15 | Los Alamos Nat Security Llc | PLASMIDES AND PACKAGING CELL LINES FOR USE IN A PHAG DISPLAY |
| EP2009990B1 (en) * | 2006-04-07 | 2016-09-21 | The Board of Regents of The University of Texas System | Methods and compositions related to adenoassociated virus-phage particles |
| JP2013527753A (ja) | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
| GB201308742D0 (en) | 2013-05-15 | 2013-06-26 | Imp Innovations | Bacteriophage |
| GB201308745D0 (en) | 2013-05-15 | 2013-06-26 | Imp Innovations | Bacteriophage |
| WO2015105806A2 (en) | 2014-01-07 | 2015-07-16 | Oklahoma Medical Research Foundation | Antibodies against glioma biomarkers |
| AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| GB201519303D0 (en) | 2015-11-02 | 2015-12-16 | Imp Innovations Ltd | Phagemid vector |
| GB201706451D0 (en) | 2017-04-24 | 2017-06-07 | Imp Innovations Ltd | Cancer treatment |
-
2015
- 2015-11-02 GB GBGB1519303.0A patent/GB201519303D0/en not_active Ceased
-
2016
- 2016-10-31 CA CA3040230A patent/CA3040230A1/en active Pending
- 2016-10-31 DK DK16790687.4T patent/DK3371315T3/da active
- 2016-10-31 EP EP22192071.3A patent/EP4163382A1/en active Pending
- 2016-10-31 US US15/772,961 patent/US11603540B2/en active Active
- 2016-10-31 EP EP16790687.4A patent/EP3371315B1/en active Active
- 2016-10-31 JP JP2018521571A patent/JP7068166B2/ja active Active
- 2016-10-31 WO PCT/GB2016/053366 patent/WO2017077275A1/en not_active Ceased
-
2022
- 2022-04-28 JP JP2022075036A patent/JP2022115934A/ja active Pending
- 2022-09-29 US US17/956,257 patent/US12331308B2/en active Active
-
2024
- 2024-05-09 JP JP2024076613A patent/JP2024102282A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533949A5 (enExample) | ||
| US12331308B2 (en) | Phagemid vector | |
| Das et al. | Gene therapies for cancer: strategies, challenges and successes | |
| JP5697042B2 (ja) | 遺伝子発現を上昇させるシステム及び該システムを保持したベクター | |
| Cody et al. | Armed replicating adenoviruses for cancer virotherapy | |
| US9689000B2 (en) | Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence | |
| HK1244679A1 (zh) | 用於治疗癌症的溶瘤腺病毒 | |
| JP2008545406A5 (enExample) | ||
| Wang et al. | Potential cancer gene therapy by baculoviral transduction | |
| US20100233125A1 (en) | Chimeric adenovirus, method for producing the same and pharmaceutical using the same | |
| Talkar et al. | Gene therapy for prostate cancer: a review | |
| JP2022500013A (ja) | グリコーゲンシンターゼキナーゼ−３（ｇｓｋ３）のコード領域を含む複製能力ある組換えウイルス及び異常細胞を殺す方法 | |
| WO2012163119A1 (zh) | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 | |
| Ulasov et al. | Oncolytic adenoviruses: a thorny path to glioma cure | |
| KR102474732B1 (ko) | 아데노바이러스 단백질 vi 유래 펩티드를 포함하는 세포 내 전달용 조성물 및 이를 포함하는 항암용 약제학적 조성물 | |
| Paul et al. | Recombinant baculovirus as a highly potent vector for gene therapy of human colorectal carcinoma: molecular cloning, expression, and in vitro characterization | |
| JP5733705B2 (ja) | 特異的プロモーターの活性を上昇させるシステム及び該システムを保持したベクター | |
| KR100912270B1 (ko) | 표적화된 유전자 전달을 위한 아데노-부속 바이러스 혈청형5 벡터 | |
| CN100429316C (zh) | 一种重组腺病毒及其应用 | |
| Zhang et al. | Random integration analysis of recombinant adeno-associated virus 6 packaged in Sf9 insect cells | |
| Pereyra et al. | Gene delivery systems | |
| EP1533381B1 (en) | Adenovirus vector | |
| WO2006125381A1 (en) | Tumor targeting gene-virus zd55-il-24, construction method and application thereof | |
| CN120958136A (zh) | 噬菌体载体 | |
| WO2025125692A1 (en) | Viral vector for transduction of adipocytes |